Zaki Elmaghraby, MD
Critical Care Medicine · Palm Bay, FLNPI 1659392785
Payments from drug & device makers
Across 148 payments — averaging $95.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- Actelion Pharmaceuticals, Ltd$4K
- Bayer$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Philips North America LLC$1K
- Regeneron Healthcare Solutions, Inc.$627
- plus $921 from 14 others
What the payments were for
- Consulting fees$1,50014%
- Speaking & faculty fees$4,46043%
- Food & beverage$4,11139%
- Education$4174%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $4,655 |
| Actelion Pharmaceuticals, Ltd | 1 | $3,600 |
| Bayer | 4 | $1,581 |
| Actelion Pharmaceuticals US, Inc. | 14 | $1,392 |
| Philips North America LLC | 69 | $1,313 |
| Regeneron Healthcare Solutions, Inc. | 18 | $627 |
| Sanofi | 9 | $254 |
| Genentech USA, Inc. | 7 | $149 |
| Harmony Biosciences LLC | 2 | $94 |
| Olympus America Inc. | 1 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| GSK | 3 | $49 |
| Fisher & Paykel Healthcare Inc | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Merck | 2 | $39 |
| Resmed Corp | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Sandoz | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,088 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 67 | $1,566,878 |
| UptraviSelexipag | 42 | $946,658 |
| OpsumitMacitentan | 65 | $798,715 |
| Orenitram ErTreprostinil Diolamine | 35 | $408,686 |
| Dupixent PenDupilumab | 34 | $123,316 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $112,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $56,069 |
| Sildenafil Citrate | 65 | $42,717 |
| Incruse ElliptaUmeclidinium Bromide | 69 | $36,703 |
| Spiriva RespimatTiotropium Bromide | 23 | $24,424 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $21,594 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,285 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $9,642 |
| DuleraMometasone/Formoterol | 21 | $7,550 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $7,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,392 | $1,745,373107 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $49 | $105,058152 claims |
| Boehringer IngelheimSpiriva Respimat | $4,655 | $24,42423 claims |
| MerckDulera | $39 | $7,55021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Palm Bay
- Jeffrey LevyHollywood$19M
- Ahmad AswadMiami$6.6M
- George DuvallVero Beach$6M
- Fortune AlabiKissimmee$3.2M
- Carlos VacaMiami$3M
- Debabrata BandyopadhyayTampa$1.9M
- Christopher HardenGainesville$713K
- Fred UmehKissimmee$682K
- Ali AtayaGainesville$672K
- George AzarFt Lauderdale$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.